Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)
China · Delayed Price · Currency is CNY 27.43
+0.29 (1.07%)
Jun 18, 2026, 3:00 PM CST
SHA:688076 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,927 | 1,940 | 1,623 | 1,033 | 648.03 | 641.71 |
Other Revenue | 2.69 | 2.69 | 1.99 | 0.82 | 3.26 | 2.16 |
| 1,930 | 1,943 | 1,625 | 1,034 | 651.29 | 643.87 | |
Revenue Growth (YoY) | 5.21% | 19.57% | 57.21% | 58.69% | 1.15% | 13.58% |
Cost of Revenue | 851.25 | 809.46 | 575.05 | 444.27 | 307.94 | 306.3 |
Gross Profit | 1,079 | 1,133 | 1,050 | 589.28 | 343.36 | 337.57 |
Selling, General & Admin | 388.99 | 418.66 | 339.13 | 268.23 | 186.98 | 150.49 |
Research & Development | 226.57 | 251.92 | 227.45 | 124.89 | 69.47 | 63.09 |
Other Operating Expenses | -12.18 | -5.84 | 1.7 | 0.02 | 9.25 | 5.24 |
Operating Expenses | 627.57 | 669.31 | 588.89 | 398.25 | 271.58 | 220.47 |
Operating Income | 451.36 | 464.03 | 460.86 | 191.04 | 71.78 | 117.1 |
Interest Expense | -68.75 | -65.46 | -34.75 | -16.09 | -9.26 | -6.12 |
Interest & Investment Income | 11.87 | 12.19 | 9.05 | 9.11 | 28.54 | 8.38 |
Currency Exchange Gain (Loss) | -4.02 | -4.02 | 8.68 | -1.38 | 1.03 | -1.58 |
Other Non Operating Income (Expenses) | -9.92 | 1.19 | -0.58 | -0.47 | -0.3 | -0 |
EBT Excluding Unusual Items | 380.54 | 407.94 | 443.26 | 182.22 | 91.79 | 117.78 |
Impairment of Goodwill | - | - | - | - | - | -1.28 |
Gain (Loss) on Sale of Investments | 1.49 | 1.49 | -2.79 | 0.26 | -1.96 | 0.13 |
Gain (Loss) on Sale of Assets | -2.43 | -2.2 | -9.2 | -15.06 | 18.44 | -0.97 |
Asset Writedown | -14.08 | -14.45 | -0.33 | - | - | - |
Other Unusual Items | -31.89 | -32.28 | 7.57 | 5.71 | 14.9 | 10.07 |
Pretax Income | 333.62 | 360.49 | 438.5 | 173.13 | 123.16 | 125.73 |
Income Tax Expense | 29.2 | 35.08 | 38.69 | 7.67 | 0.39 | 16.92 |
Earnings From Continuing Operations | 304.42 | 325.41 | 399.82 | 165.45 | 122.77 | 108.81 |
Minority Interest in Earnings | 4.84 | 7.01 | 4.57 | -2.52 | 6.34 | 6.58 |
Net Income | 309.27 | 332.42 | 404.39 | 162.94 | 129.11 | 115.39 |
Net Income to Common | 309.27 | 332.42 | 404.39 | 162.94 | 129.11 | 115.39 |
Net Income Growth | -36.97% | -17.80% | 148.19% | 26.20% | 11.89% | -6.52% |
Shares Outstanding (Basic) | 316 | 314 | 302 | 300 | 296 | 269 |
Shares Outstanding (Diluted) | 316 | 314 | 309 | 300 | 296 | 269 |
Shares Change (YoY) | 2.28% | 1.59% | 2.86% | 1.28% | 10.06% | 19.95% |
EPS (Basic) | 0.98 | 1.06 | 1.34 | 0.54 | 0.44 | 0.43 |
EPS (Diluted) | 0.98 | 1.06 | 1.31 | 0.54 | 0.44 | 0.43 |
EPS Growth | -38.38% | -19.08% | 141.30% | 24.60% | 1.66% | -22.07% |
Free Cash Flow | -497.41 | -685.77 | -690.01 | -310.43 | -409.07 | -52.61 |
Free Cash Flow Per Share | -1.57 | -2.19 | -2.23 | -1.03 | -1.38 | -0.20 |
Dividend Per Share | 0.350 | 0.350 | 0.643 | 0.286 | 0.143 | 0.107 |
Dividend Growth | -45.56% | -45.56% | 125.03% | 99.93% | 33.43% | - |
Gross Margin | 55.90% | 58.34% | 64.61% | 57.02% | 52.72% | 52.43% |
Operating Margin | 23.38% | 23.89% | 28.36% | 18.48% | 11.02% | 18.19% |
Profit Margin | 16.02% | 17.11% | 24.89% | 15.77% | 19.82% | 17.92% |
Free Cash Flow Margin | -25.77% | -35.30% | -42.47% | -30.04% | -62.81% | -8.17% |
EBITDA | 776.98 | 765.05 | 663.47 | 322.81 | 170.52 | 198.73 |
EBITDA Margin | 40.25% | 39.38% | 40.83% | 31.23% | 26.18% | 30.87% |
D&A For EBITDA | 325.62 | 301.02 | 202.61 | 131.77 | 98.75 | 81.63 |
EBIT | 451.36 | 464.03 | 460.86 | 191.04 | 71.78 | 117.1 |
EBIT Margin | 23.38% | 23.89% | 28.36% | 18.48% | 11.02% | 18.19% |
Effective Tax Rate | 8.75% | 9.73% | 8.82% | 4.43% | 0.32% | 13.46% |
Revenue as Reported | 1,930 | 1,943 | 1,625 | 1,034 | 651.29 | 643.87 |
Advertising Expenses | - | 0.18 | 1.62 | - | - | - |